Yeoun Jin Kim, Executive Director of Biomarker Science and Technologies at AstraZeneca, shared a post on LinkedIn:
“I am excited to share that I have stepped into a new role as Executive Director.
While continuing to lead the Translational Proteomics group within Biomarker Science and Technologies (BST) at AstraZeneca, this new role will focus on shaping the future of Precision Medicine and exploring new opportunities beyond what is possible today.
I am grateful to my team, colleagues, and leadership for their trust, collaboration, and shared vision of the transformative potential of clinical proteomics.
Thank you to everyone who has been part of this journey. I look forward to the opportunities ahead.”
Other articles about AstraZeneca on OncoDaily.